Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.69 |
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | RAB9A | P51151 | 7/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.56 |
| ▸ | RELA | Q04206 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30566761 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL22796349 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL27918922 | 0.81 | HPGD (0.64) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL27475343 | 0.81 | ALDH1A1 (0.59) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL11920156 | 0.81 | RAB9A (0.67) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL29077243 | 0.81 | ALDH1A1 (0.59) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL28529043 | 0.81 | HPGD (0.61) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL10907132 | 0.79 | NOTUM (0.59) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL2640764 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL5901255 | 0.77 | ALDH1A1 (0.54) | SMN1; SMN2NPC1RAB9AHPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300932-A1 | N-PHENYLIMINE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | GUIZHOU UNIVERSITY (CN) | 2024-09-12 | — | — | US | disclosed |
| WO-2024174317-A1 | N-PHENYLIMINE-CONTAINING DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 贵州大学 | 2024-08-29 | — | — | WO | disclosed |
| CN-116731003-A | N-phenylimine-containing derivative, and preparation method and application thereof | 贵州大学 | 2023-09-12 | — | — | CN | disclosed |
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2539326-B1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-25 | — | — | US | disclosed |
| US-9187466-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| EP-2539326-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300932-A1 | N-PHENYLIMINE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | PNMT, NNMT, PAH | SMN1; SMN2 1700/4885NPC1 1387/4885RAB9A 4798/4885 |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | SMN1; SMN2 2876/4885NPC1 986/4885RAB9A 4431/4885 |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | SMN1; SMN2 2876/4885NPC1 986/4885RAB9A 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.